Research programme: antibody based therapeutics - Celgene/Sutro

Drug Profile

Research programme: antibody based therapeutics - Celgene/Sutro

Alternative Names: Antibody-drug conjugates - Celgene/Sutro; Bispecific antibody - Celgene/Sutro; Multispecific antibodies targeting immuno-onchology - Celgene/Sutro; Therapeutic antibody - Celgene/Sutro

Latest Information Update: 10 Jan 2015

Price : $50

At a glance

  • Originator Celgene Corporation; Sutro Biopharma
  • Class Antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Oct 2014 Celgene and Sutro Biopharma enters into collaboration agreement for the development of antibody based therapeutics
  • 01 Dec 2012 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top